A Comparative Evaluation of Hydroxycamptothecin Drug Nanorods With and Without Methotrexate Prodrug Functionalization for Drug Delivery by Fuqiang Guo et al.
NANO EXPRESS Open Access
A Comparative Evaluation of
Hydroxycamptothecin Drug Nanorods
With and Without Methotrexate Prodrug
Functionalization for Drug Delivery
Fuqiang Guo1†, Zhongxiong Fan1†, Jinbin Yang3, Yang Li2, Yange Wang2, Hai Zhao1, Liya Xie4*
and Zhenqing Hou1,2*
Abstract
We developed a novel self-targeted multi-drug co-delivery system based on rod-shaped 10-hydroxycamptothecin
(CPT) nanoanticancer drug (CPT NRs) followed by a surface functionalization with self-targeting PEGylated
lipid-conjugated methotrexate (MTX) pro-anticancer drug. The self-targeting effect and in vitro cell viability
of the MTX-PEG-CPT NRs on HeLa cells were demonstrated by comparative cellular uptake and MTT assay of
the PEG-CPT NRs. In vitro studies showed the feasibility of using this high drug-loading MTX-PEG-CPT NRs in
self-targeted drug delivery, controlled-/sustained-release, and synergistic cancer therapy. More importantly, this
work would stimulate interest in the use of PEGylated lipid-conjugated MTX by introducing an early-phase
tumor-targeting role and then driving a late-phase anticancer role for the highly convergent design of nanomulti-drug,
which may advantageously offer a new and simple strategy for simultaneously targeting and treating FA
receptor-overexpressing cancer cells.
Keywords: Self-targeted multi-drug co-delivery system, 10-Hydroxycamptothecin, Methotrexate, Controlled and
sustained release
Background
Combination therapy has been considered to be a prom-
ising strategy for cancer treatment [1, 2]. Nanoparticles
with multi-therapeutic actions targeted to different ac-
tion sites of target cell could more effectively reduce the
blood/renal clearance, increase the tumor accumulation,
and, more importantly, induce the apoptosis/death and
inhibit the growth of cancer cells [3]. In recent years,
nanoparticles with chemo-chemo, chemo-gene, chemo-
thermal, and chemo-photodynamic combination therap-
ies have attracted considerable attention [4]. Especially,
thousands of nanoparticles with chem-chem combin-
ation therapy have been widely used in treatment of
many types of tumor. For the combination cancer
chemotherapy, to achieve the synergistic anticancer ef-
fect, overcome the drug resistance, and reduce the side
effects, multi-anticancer drugs have been co-loaded
within the nanoscaled drug carriers of inert carrier mate-
rials and co-delivered to the tumor. However, when
these drug carriers with comparatively low drug-loading
ability (typically < 20 %) were clinically used for cancer
treatment, the considerable decrease of effective accu-
mulation of drug would occurred at the tumor site;
in addition, large amounts of inert drug carriers could
impose additional burden on the patients such as dosage-
related systemic toxicity, metabolism/excretion/degrad-
ation concern, and serious inflammation [5, 6].
Anticancer drug [7], anticancer drug-anticancer drug
physical complex [8], and anticancer drug-anticancer
drug chemical conjugate [9, 10] as a material to con-
struct the drug nanocrystals or nanoparticles (carrier-
free nanoscaled drug system, self-delivery nanodrug)
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without (or with little) addition of any inert carrier ma-
terials have become attractive and have demonstrated
the superior performance in the field of drug delivery for
cancer treatment. However, insufficient bioenvironmen-
tal stability [11] or poor-targeting efficiency seriously
limited its further clinical application. Our previous
study demonstrated that methotrexate (MTX) anticancer
drug itself could also be utilized as a folic acid (FA)
receptor-overexpressing cancer cell-specific “targeting lig-
and,” playing a dual role [12, 13]. Inspired and motivated by
the unique advantage of drug self-constructed nanoparticles
and potential merits of therapeutic agent with a dual role,
one would envisage the possibility of designing a self-
targeting and high-drug loading nanomulti-drug to simply
achieve the more effectively and specifically cell-targeting
effect and cell-killing efficacy against cancer cell. The highly
convergent design of self-targeting nanomulti-drug by “self-
targeted multi-drug co-delivery and combination cancer
therapy” may open a promising new door to nanomedicine.
Results and discussion
Herein, we proposed a new strategy of preparing self-
carried pure 10-hydroxycamptothecin (CPT) nanoparti-
cles to form a hydrophobic drug (CPT) via solvent ex-
change followed by surface functionalization of self-
targeting amphiphilic prodrug (Fig. 1) for self-targeted
multi-drug co-delivery, cancer diagnosis, and combination
cancer therapy (Fig. 2a, b). It is well known that each type
of the drug has its unique inhibition mechanism or antitu-
mor target [14]. For instance, MTX controls cancer by
inhibiting dihydrofolate reductase (DHFR), which inter-
feres with nucleic acid synthesis [15], while CPT controls
cancer by inhibiting replication of DNA and transcription
of RNA [16, 17]. Moreover, MTX could be not only uti-
lized as an anticancer drug but also a cancer cell-specific
targeting ligand because of its high structural similarity to
FA. If both MTX and CPT drugs were combined in thera-
peutic treatment of FA receptor-overexpressing cancer
cells, it is expected that their anticancer activity can be en-
hanced because of the self-introducing of targeting effect
and achievement of synergistic anticancer efficacy of two
types of drugs with different pharmaceutical functions, ac-
tion modes, and anticancer mechanisms.
To obtain CPT-MTX composite nanomedicine, CPT
was firstly dissolved in ethanol, and then, the mixture
was added to water under ultrasonication for solvent
exchange; finally, the resulted rod-shaped CPT drug
nanoparticles (CPT NRs) were absorbed by DSPE-PEG-
MTX (its structure was confirmed by 1H nuclear mag-
netic resonance (1H NMR, Additional file 1: Figure S1,
ESI†), Fourier transform infrared spectroscopy (FTIR,
Additional file 1: Figure S2, ESI†), and matrix-assisted
laser desorption/ionization time of flight mass spectrom-
etry (MALDI-TOF-MS, Additional file 1: Figure S3, ESI†)
via hydrophobic interactions between the hydrophobic
surface of NRs and the long-chain fatty acids of phospho-
lipid of DSPE-PEG-MTX (designed as MTX-PEG-CPT
NRs)). During the preparing process, ultrasonication was
used to accelerate the diffusion of ethanol into water,
resulting in the strong supersaturation and high nucle-
ation rates to produce uniform nanosuspension. The
addition of self-targeting PEGylated lipid prodrug to the
hydrophilic region of the CPT NRs by non-covalent asso-
ciation resulted in the production of CPT NRs core-MTX
shell-constructing MTX-PEG-CPT NRs with good water
dispersibility, stability, and long-circulating ability.
Fig. 1 Schematic illustration of the construct of the CPT NRs by solvent exchange followed by the surface functionalization of DSPE-PEG-MTX or
DSPE-MPEG (designed as MTX-PEG-CPT NRs or PEG-CPT NRs)
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The images observed by scanning electron microscopy
(SEM) and transmission electron microscopy (TEM)
showed the MTX-PEG-NRs were in dimensions of 1–
2 μm/50–100 nm with rod shape (Fig. 3a, b). It was usu-
ally reported that the rod-shaped particles (higher aspect
ratios) showed more obvious advantages compared with
the sphere-shaped ones (lower aspect ratios) in vitro drug
release, in vitro cellular uptake, and in vivo blood circula-
tion/tumor accumulation [18–20]. The result determined
by dynamic light scattering (DLS) and static light scatter-
ing (SLS) showed that the MTX-PEG-NRs had an average
hydrodynamic particle size of nearly 250 nm with a nar-
row particle size distribution and a negative surface charge
of about −30 mV (Fig. 3c, d). The CPT drug-loading
content and MTX drug-loading content determined by
high-performance liquid chromatography (HPLC) were,
respectively, 74.8 ± 2.3 % and 2.6 ± 0.4 %. It was reported
that the particle size of nanoparticles designed for in vivo
drug delivery to tumor sites should be between 100 and
600 nm because vasculature of tumors varies from 100 to
600 nm [21]. Also, nanoparticles with positive surface
charge and hydrophobic surface could promote protein
adsorption and reticuloendothelial clearance [22]. There-
fore, these physiochemical characteristics of the MTX-
PEG-CPT NRs were favorable for reducing the inert ma-
terial usage, achieving the good physiological stability, and
acquiring the suitable passive tumor-targeting effect via
the enhanced penetration and retention (EPR) effect,
which simultaneously make drug delivery/cancer therapy
combined with cancer imaging possible. In addition, the
physiochemical characteristic including hydrodynamic
particle size, surface charge, bioenvironmental stability
(discussed below), and CPT drug-loading content was
similar (Table 1); hence, the PEG-NRs could be used as a
reference for in vitro and in vivo evaluations.
To evaluate the bioenvironmental stability of the MTX-
PEG-CPT NRs, we determined the average hydrodynamic
particle size and fluorescence intensity of the MTX-PEG-
CPT NRs in phosphate-buffered saline (PBS) during 3 days
of incubation period by DLS and fluorescence analysis
(Fig. 3e, f ). PEG-CPT NRs and MTX-PEG-CPT NRs show
a no significant increase of average hydrodynamic particle
size and decrease of fluorescence intensity. These results
indicated the PEG-CPT NRs and MTX-PEG-CPT NRs
possessed good bioenvironmental stability, whereas the
CPT NRs observably form the large agglomerates and ag-
gregation because of the charge elimination on the surface
of CPT NRs by zwitterionic phosphonates of PBS. In
addition, the MTX-PEG-CPT NRs also showed no signifi-
cant change of hydrodynamic particle size and fluores-
cence intensity in Dulbecco’s modified Eagle medium with
fetal bovine serum (10 %) (Additional file 1: Figure S4,
ESI†). These results demonstrated the protecting effect of
PEG on the MTX-PEG-CPT NRs against the zwitterion
effect and protein adsorption by the combination of
hydration effect and steric effect [23, 24].
The drug release profile of the MTX-PEG-CPT NRs is of
great importance for multi-drug co-delivery applications.
Fig. 2 a Illustration of drug delivery of the PEG-CPT NRs. Once intravenously administrated, the PEG-CPT NRs were accumulated at the tumor site
by the enhanced permeability and retention (EPR) effect-mediated passive tumor-targeting mechanism, were internalized by the tumor
cells endocytosis, released CPT in a sustained manner, and intracellularly delivered CPT to the nucleus. b The MTX-PEG-CPT NRs with MTX
self-targeting ligand enter tumor cells by FA receptor-mediated endocytosis and released both CPT and MTX anticancer drugs in tumor
cells to be, respectively, delivered to nucleus and cytoplasm (CPT binds to DNA in the nucleus, and MTX binds to DHFR enzyme in the
cytoplasm) for self-targeted multi-drug co-delivery and combination cancer therapy
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As shown in Fig. 3g, during the first phase of 8 h, the accu-
mulative CPT release of the MTX-PEG-CPT NRs exhib-
ited about 25 %. And both of these CPT NRs exhibited a
similar CPT release behavior, which indicated the introduc-
tion of MTX-targeting ligand/anticancer drug did not alter
the drug release of PEGylated CPT NRs with long-chain-
length PEG. It was worthy noted that these two types of
CPT NRs exhibited no early-phase serious burst release
but a sustained and steady release characteristic. The result
was explained by the fact that CPT with the crystalline
state but not the amorphous one effectively avoids an
unstable spatial arrangement, which is essential for their in
vivo applications because of the reduced drug burst release
in blood circulation, enhanced blood circulation effect, and
improved tumor-targeted drug delivery.
We further studied the MTX release of the MTX-
PEG-CPT NRs in PBS with different pH values in the
presence or absence of proteases (pH 7.4 without prote-
ases simulates blood circulation conditions, pH 5.0 with
proteases simulates tumor cells lysosome). As depicted
in Fig. 3h, at pH 7.4 in the absence of proteases, the
accumulative MTX release of the MTX-PEG-CPT NRs
at 24 h reached no more than 10 %. In sharp contrast,
the addition of enzyme as well as the decrease of pH sig-
nificantly promoted the MTX release from the MTX-
PEG-CPT NRs. For instance, at pH 5.0 in the presence
of proteases, the accumulative release of MTX greatly
increased to about 45 % 24 h. This result indicated that
the chemical linkage between MTX and MTX-PEG-CPT
NRs was cleavaged by the combination of enzyme and
Fig. 3 a SEM (scale bars 1 μm) (inset of a) tyndall effect. b TEM (scale bars 200 nm) (inset of b) LCSM image. c Hydrodynamic particle size
distribution. d Zeta potential distribution of the MTX-PEG-CPT NRs. e, f In vitro physiological stability of the MTX-PEG-CPT NRs in PBS. e Hydrodynamic
particle size change. f Fluorescence intensity change. g, h In vitro drug release of the MTX-PEG-CPT NRs. g CPT drug release. h MTX drug
release. Data are presented as mean ± s. d. (n = 3)
Table 1 Hydrodynamic particle size, zeta potential, drug-loading content of the PEG-CPT NRs, and MTX-PEG-CPT NRs
Data are presented as mean ± s. d. (n = 3)
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pH to release the active MTX drug, “turn off” the target-
ing role of MTX while “turn on” the anticancer role of
MTX. These also showed the potential for the in vivo
applications such as the more effective multi-drug co-
delivery to tumor microenvironment and tumor cells with
reduced drug leakage/burst release in blood circulation.
To verify the specificity of the MTX-PEG-CPT NRs for
FA receptors, we performed a competition assay on HeLa
cells overexpressed FA receptors. HeLa cells were pre-
incubated with excess of free FA and then incubated with
the MTX-PEG-CPT NRs. The cellular uptake of the
MTX-PEG-CPT NRs by FA-treated HeLa cells was signifi-
cantly reduced in comparison with untreated HeLa cells
(Fig. 4). Consistent with our previous study [25, 26], the
result suggested that MTX-functionalized nanomulti-drug
could specifically bind to FA receptors overexpressed on
the surface of HeLa cells.
We investigated the cellular uptake of the MTX-
PEG-CPT NRs by HeLa cells using laser confocal
scanning microscopy (CLSM). The qualitative result
indicated that the functionalization of MTX improve
the cellular internalization of the MTX-PEG-CPT
NRs in comparison with the PEG-CPT NRs (Fig. 4).
We further evaluated the cellular uptake of the MTX-
PEG-CPT NRs by HeLa cells by flow cytometry. The
quantitative results indicated the significantly higher
cellular uptake efficacy of the MTX-PEG-CPT NRs
compared with the PEG-CPT NRs (Fig. 4b). All re-
sults proved that self-targeting MTX moiety enhanced
the target efficacy to potentially help the MTX-PEG-
CPT NRs enter FA receptor-overexpressing HeLa cells
by FA receptor-mediated endocytosis via multivalent
receptor-ligand interactions [27].
We next explored the in vitro cytotoxicity of the MTX-
PEG-CPT NRs toward HeLa cells compared with the free
CPT, free CPT plus free MTX, and PEG-CPT NRs by
MTTassays. As shown in Fig. 5a, the MTX-PEG-CPT NRs
showed much higher cytotoxicity than the free CPT, free
CPT plus free MTX, and PEG-CPT NRs at the same CPT
drug concentrations. The result demonstrated that the
MTX-PEG-CPT NRs can obviously exert the inhibition
effect of HeLa cell proliferation, as shown by a significant
decrease in the half-maximal inhibitory concentration
(IC50) values of the free CPT (IC50 = 9.9 μg/mL), free CPT
plus free MTX (IC50 = 7.9 μg/mL), and PEG-CPT NRs
(IC50 = 5.4 μg/mL) in comparison with the MTX-PEG-
CPT NRs (IC50 = 3.2 μg/mL) after 24 h of incubation. The
improved drug efficacy could be the more effective cellular
uptake as well as sustained/controlled drug release of the
self-targeting nanomulti-drug compared with either single-
free drug molecule or both free drug molecule.
To further verify the drug synergistic effect of the
MTX-PEG-CPT NRs, the combination index (CI),
which could supply quantitative information regarding
the extent of drug interactions, is calculated from the
following equation [10, 28].
CI ¼ Nano‐Drug1=Drug1þNano‐Drug2=Drug2
where Nano-Drug1 and Nano-Drug2 are the concentration
of the first drug and second drug of nanoparticles that in
the combination to produce a certain effect (e.g.,
Fig. 4 a CLSM images and b flow cytometry analysis of HeLa cells incubated with MTX-PEG-CPT NRs in the presence of excess of free FA,
MTX-PEG-CPT NRs, and PEG-CPT NRs for 2 h. Cell nuclei are stained with PI. Data are presented as mean ± s. d. (n = 3). *P < 0.05 compared
with the other groups
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50 % inhibition of cell viability). Drug1 and Drug2 are
the concentration of single drugs to obtain the same
effect. The CI value less than, equal to, or more than
1 is corresponding to the effect of synergism, additiv-
ity, and antagonism, respectively. As shown in Fig. 5a
and Additional file 1: Figure S5, ESI†, the CI value of
the MTX-PEG-CPT NRs was calculated as 0.35
(Fig. 5b), which indicated a highly synergistic effect of
the MTX-PEG-CPT NRs’ both drugs acting on HeLa
cell (CPT was released and delivered to the nucleus
for inhibiting DNA activity, whereas MTX to the
cytoplasm for inhibiting DHFR enzyme activity). All
results demonstrated that the FA receptor-targeted,
MTX-functionalized CPT NRs could specifically and
efficiently enter the cancer cells to controlled and
sustained release both CPT and MTX anticancer drug
for achievement of greater anticancer efficacy and
more effectively synergistic effect against HeLa cell.
Conclusions
In summary, the self-targeting, controlled-/sustained-re-
lease, and multi-drug-loaded MTX-PEG-CPT NRs
have been prepared for highly effective “self-targeted
multi-drug co-delivery and combination cancer ther-
apy.” The MTX-PEG-CPT NRs can be specifically
uptaken by cancer cells, which result in an efficient
intracellular both drug concentration and excellent
cytotoxicity. More importantly, the MTX-PEG-CPT
NRs can kill cancer cells through different functional
roles, action sites, and anticancer mechanisms of both
MTX and CPT, achieving a synergy in anticancer
activity and showing a potential for clinical treatment
of nanomedicine.
Additional file
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